Vaccine prophylaxis of viral hepatitis in patients with acute leukemia

Aim. To assess efficacy of vaccine against viral hepatitis В (VHB) in adults after achievement of acute leukemia (AL) remission. Material and methods. Specific prevention of VHB was made in 30 AL patients with recombinant vaccine Engerix В by two schemes: 0-1-2-12 and 0-1-2-6 months with double adul...

Full description

Saved in:
Bibliographic Details
Published inTerapevtic̆eskii arhiv Vol. 80; no. 7; pp. 27 - 29
Main Authors N M Gurina, E P Svedentsov, V I Shardakov, V V Cherepanova
Format Journal Article
LanguageRussian
Published "Consilium Medicum" Publishing house 01.07.2008
Subjects
acute leukemia
antibodie
polychemotherapy
vaccine prophylaxis
viral hepatitis b
Online AccessGet full text

Cover

More Information
Summary:Aim. To assess efficacy of vaccine against viral hepatitis В (VHB) in adults after achievement of acute leukemia (AL) remission. Material and methods. Specific prevention of VHB was made in 30 AL patients with recombinant vaccine Engerix В by two schemes: 0-1-2-12 and 0-1-2-6 months with double adult dose 40 mcg. Efficacy of vaccination was evaluated by the titer of antibodies to HBs-Ag (HBs-Ab) 1 month after each injection of the vaccine. The control group consisted of 36 patients. Follow-up was 6 months to 10 years. Results. Vaccine prophylaxis of VHB in AL remission resulted in appearance of the protective antibody titer after the forth vaccine injection in 50% patients. Out of 30 vaccinated patients 2 (6.7%) got infected with HBV 3 and 5 years after onset of the disease. Markers of HBV replication were detected in 8 (22%) of 36 patients. Conclusion. Vaccine prophylaxis of VHB in adult patients in AL remission was effective in 93.3% of the vaccinated patients.
ISSN:0040-3660
2309-5342